List view / Grid view
GlaxoSmithKline announced headline results from its second phase III study…
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
Novel scientific collaboration to use genomics and big data to…
27 March 2014 | By GlaxoSmithKline
Novel scientific collaboration to use genomics and big data to drive drug discovery...
GlaxoSmithKline plc announced that the European Medicines Agency’s Committee for…
21 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse®...
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines…
20 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for umeclidinium/vilanterol under the proposed brand name Anoro®...
GSK and Theravance, Inc. announced that the PADAC to the…
10 September 2013 | By GlaxoSmithKline
GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol...
“GSK fully supports the commitment made by BMJ to drive…
31 October 2012 | By GlaxoSmithKline
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data..."
GlaxoSmithKline signed a long-term agreement with the World Anti-Doping Agency...
4 July 2011 | By GlaxoSmithKline
GlaxoSmithKline signed a long-term agreement with the World Anti-Doping Agency...
